Scios Natrecor Expanded Mortality Analysis Finds Two New Patient Deaths
This article was originally published in The Pink Sheet Daily
Executive Summary
The J&J subsidiary says the deaths have “no impact on the overall benefit/risk profile” of the heart failure drug when it is prescribed as labeled.